Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728207 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01728207 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 30 participants.
The verdict
NCT01728207, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
IMMU-114 will be studied at different dose schedules and dose levels in order to assess the highest dose safely tolerated. IMMU-114 will be administered subcutaneously (under the skin). IMMU-114 will be given 1-2 times weekly for 3 weeks followed by one week of rest. This is considered one cycle. Treatment cycles will be repeated until toxicity or worsening of disease.
Interventions
- DRUG IMMU-114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01728207
The ClinicalTrials.gov registry entry for NCT01728207 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMMU-114 is the first listed.
NCT01728207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01728207 about?
NCT01728207 is a clinical study titled "Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL". IMMU-114 will be studied at different dose schedules and dose levels in order to assess the highest dose safely tolerated. IMMU-114 will be administered subcutaneously (under the skin). IMMU-114 will be given 1-2 times weekly for 3 weeks followed by one week of rest. This is considered one cycle. Tr...
What is the current status of trial NCT01728207?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-03. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01728207?
The interventions under investigation include: IMMU-114 (DRUG).
Who is sponsoring clinical trial NCT01728207?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.